TetraVax-DV Vaccine - Admixture TV003

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Butantan Institute

Conditions

Dengue

Phase 1

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

CompletedNCT01436422

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2011-08-31End: 2014-03-31Updated: 2015-08-20

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

CompletedNCT01506570

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2011-12-31End: 2013-09-30Updated: 2015-08-20

Phase 2

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Butantan InstituteDengue

Start: 2013-10-31End: 2020-12-31Updated: 2019-01-16

Related Papers

Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort

Frontiers in Immunology2022-06-284 citations

Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.

2020-03-2469 citations

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination

PLoS neglected tropical diseases2017-05-0899 citations

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

The Journal of Infectious Diseases2015-03-22195 citations